<SEC-DOCUMENT>0001075880-13-000080.txt : 20131009
<SEC-HEADER>0001075880-13-000080.hdr.sgml : 20131009
<ACCEPTANCE-DATETIME>20131008184915
ACCESSION NUMBER:		0001075880-13-000080
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20131009
FILED AS OF DATE:		20131009
DATE AS OF CHANGE:		20131008

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NOVOGEN LTD
		CENTRAL INDEX KEY:			0001075880
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-29962
		FILM NUMBER:		131142192

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 1
		STREET 2:		16 - 20  EDGEWORTH DAVID AVE
		CITY:			HORNSBY NSW
		STATE:			C3
		ZIP:			2077
		BUSINESS PHONE:		01161298780088

	MAIL ADDRESS:	
		STREET 1:		LEVEL 1
		STREET 2:		16 - 20  EDGEWORTH DAVID AVE
		CITY:			HORNSBY NSW
		STATE:			C3
		ZIP:			2077
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>asxannouncement1a1310id.htm
<DESCRIPTION>CONVERTED BY EDGARWIZ
<TEXT>
<!doctype html public "-//IETF//DTD HTML//EN">
<HTML>
<HEAD>
<TITLE>Converted by EDGARwiz</TITLE>
</HEAD>
<BODY style="margin-top:0;font-family:Times New Roman; font-size:10pt; color:#000000">
<DIV style="width:625.267px"><P style="margin-top:96px; margin-bottom:0px"><img src="asxannouncement1a1310id001.jpg" alt="[asxannouncement1a1310id001.jpg]" align=bottom height=70 width=550></P>
<P style="margin-top:27.933px; margin-bottom:0px; font-family:Calibri,Times New Roman; font-size:14pt"><B>ASX RELEASE</B></P>
<P style="margin-top:26.8px; margin-bottom:0px; font-family:Calibri,Times New Roman; font-size:14pt"><B>Novogen acquires new technology to add to its oncology drug pipeline</B></P>
<P style="margin-top:22.133px; margin-bottom:0px; font-family:Calibri,Times New Roman; font-size:11pt"><B>9</B><FONT style="font-size:9.1pt"><B> &nbsp;</B></FONT><B>October</B><FONT style="font-size:8.85pt"><B> &nbsp;</B></FONT><B>2013,</B><FONT style="font-size:8.8pt"><B> &nbsp;</B></FONT><B>Sydney</B><FONT style="font-size:8.8pt"><B> &nbsp;</B></FONT><B>Australia:</B><FONT style="font-size:8.65pt"> &nbsp;</FONT>Novogen<FONT style="font-size:8.2pt"> &nbsp;</FONT>Limited<FONT style="font-size:8.4pt"> &nbsp;</FONT>(ASX:NRT)<FONT style="font-size:8.7pt"> &nbsp;</FONT>has<FONT style="font-size:8.2pt"> &nbsp;</FONT>acquired<FONT style="font-size:8.1pt"> &nbsp;</FONT>a<FONT style="font-size:8.45pt"> &nbsp;</FONT>novel<FONT style="font-size:8.45pt"> &nbsp;</FONT>drug</P>
<P style="margin-top:3.2px; margin-bottom:0px; font-family:Calibri,Times New Roman; font-size:11pt">technology that will be developed as a potentially major class of cancer drugs known as anti-</P>
<P style="margin-top:3.2px; margin-bottom:0px; font-family:Calibri,Times New Roman; font-size:11pt">tropomyosins<FONT style="font-size:7.7pt"> &nbsp;</FONT>(anti-Tms).<FONT style="font-size:7.4pt"> &nbsp;</FONT>Anti-Tm<FONT style="font-size:7.8pt"> &nbsp;</FONT>drugs<FONT style="font-size:7.65pt"> &nbsp;</FONT>will<FONT style="font-size:7.55pt"> &nbsp;</FONT>join<FONT style="font-size:7.5pt"> &nbsp;</FONT>the<FONT style="font-size:7.4pt"> &nbsp;</FONT>Company<font style='font-family:Arial Unicode MS,Times New Roman'>&#8217;</font>s<FONT style="font-size:7.65pt"> &nbsp;</FONT>growing<FONT style="font-size:7.5pt"> &nbsp;</FONT>pipeline<FONT style="font-size:7.7pt"> &nbsp;</FONT>of<FONT style="font-size:7.65pt"> &nbsp;</FONT>super-</P>
<P style="margin-top:3.2px; margin-bottom:0px; font-family:Calibri,Times New Roman; font-size:11pt">benzopyran drugs, including Trilexium and related analogs.</P>
<P style="margin-top:21.067px; margin-bottom:0px; font-family:Calibri,Times New Roman; font-size:11pt">The<FONT style="font-size:7.95pt"> &nbsp;</FONT>target<FONT style="font-size:7.75pt"> &nbsp;</FONT>of<FONT style="font-size:7.6pt"> &nbsp;</FONT>anti-Tm<FONT style="font-size:8pt"> &nbsp;</FONT>drugs<FONT style="font-size:8.05pt"> &nbsp;</FONT>is<FONT style="font-size:7.6pt"> &nbsp;</FONT>the<FONT style="font-size:8pt"> &nbsp;</FONT>protein,<FONT style="font-size:7.7pt"> &nbsp;</FONT>Tm5NM1,<FONT style="font-size:7.8pt"> &nbsp;</FONT>an<FONT style="font-size:7.8pt"> &nbsp;</FONT>integral<FONT style="font-size:7.6pt"> &nbsp;</FONT>part<FONT style="font-size:7.65pt"> &nbsp;</FONT>of<FONT style="font-size:7.6pt"> &nbsp;</FONT>the<FONT style="font-size:7.4pt"> &nbsp;</FONT>microfilament</P>
<P style="margin-top:3.2px; margin-bottom:0px; font-family:Calibri,Times New Roman; font-size:11pt">component<FONT style="font-size:6.65pt"> &nbsp;</FONT>of<FONT style="font-size:6.55pt"> &nbsp;</FONT>the<FONT style="font-size:6.45pt"> &nbsp;</FONT>cytoskeleton<FONT style="font-size:6.25pt"> &nbsp;</FONT>of<FONT style="font-size:6.55pt"> &nbsp;</FONT>a<FONT style="font-size:6.55pt"> &nbsp;</FONT>cell.<FONT style="font-size:6.5pt"> &nbsp;</FONT>Inhibition<FONT style="font-size:6.6pt"> &nbsp;</FONT>of<FONT style="font-size:6.3pt"> &nbsp;</FONT>Tm5NM1<FONT style="font-size:6.5pt"> &nbsp;</FONT>effectively<FONT style="font-size:6.65pt"> &nbsp;</FONT>blocks<FONT style="font-size:6.6pt"> &nbsp;</FONT>the<FONT style="font-size:6.6pt"> &nbsp;</FONT>ability</P>
<P style="margin-top:3.2px; margin-bottom:0px; font-family:Calibri,Times New Roman; font-size:11pt">of a cancer cell to function and to divide.</P>
<P style="margin-top:20.867px; margin-bottom:0px; font-family:Calibri,Times New Roman; font-size:11pt">The<FONT style="font-size:6.9pt"> &nbsp;</FONT>cytoskeleton<FONT style="font-size:6.8pt"> &nbsp;</FONT>is<FONT style="font-size:6.55pt"> &nbsp;</FONT>so-called<FONT style="font-size:6.8pt"> &nbsp;</FONT>because<FONT style="font-size:6.9pt"> &nbsp;</FONT>it<FONT style="font-size:6.85pt"> &nbsp;</FONT>gives<FONT style="font-size:6.9pt"> &nbsp;</FONT>a<FONT style="font-size:6.55pt"> &nbsp;</FONT>cell<FONT style="font-size:6.85pt"> &nbsp;</FONT>its<FONT style="font-size:6.85pt"> &nbsp;</FONT>shape<FONT style="font-size:6.9pt"> &nbsp;</FONT>and<FONT style="font-size:6.8pt"> &nbsp;</FONT>form,<FONT style="font-size:6.85pt"> &nbsp;</FONT>but<FONT style="font-size:6.65pt"> &nbsp;</FONT>more<FONT style="font-size:6.9pt"> &nbsp;</FONT>relevantly</P>
<P style="margin-top:3.2px; margin-bottom:0px; font-family:Calibri,Times New Roman; font-size:11pt">serves<FONT style="font-size:6.35pt"> &nbsp;</FONT>a<FONT style="font-size:6.3pt"> &nbsp;</FONT>wide<FONT style="font-size:6.3pt"> &nbsp;</FONT>range<FONT style="font-size:6.35pt"> &nbsp;</FONT>of<FONT style="font-size:6.3pt"> &nbsp;</FONT>functions<FONT style="font-size:6.35pt"> &nbsp;</FONT>that<FONT style="font-size:6.6pt"> &nbsp;</FONT>actively<FONT style="font-size:6.4pt"> &nbsp;</FONT>contribute<FONT style="font-size:6.4pt"> &nbsp;</FONT>to<FONT style="font-size:6.25pt"> &nbsp;</FONT>the<FONT style="font-size:6.35pt"> &nbsp;</FONT>ability<FONT style="font-size:6.15pt"> &nbsp;</FONT>of<FONT style="font-size:6.3pt"> &nbsp;</FONT>a<FONT style="font-size:6.3pt"> &nbsp;</FONT>cell<FONT style="font-size:6.65pt"> &nbsp;</FONT>to<FONT style="font-size:6.45pt"> &nbsp;</FONT>survive,<FONT style="font-size:6.2pt"> &nbsp;</FONT>to</P>
<P style="margin-top:3.2px; margin-bottom:0px; font-family:Calibri,Times New Roman; font-size:11pt">move, and to divide.</P>
<P style="margin-top:21.067px; margin-bottom:0px; font-family:Calibri,Times New Roman; font-size:11pt">Drugs<FONT style="font-size:9.55pt"> &nbsp;</FONT>that<FONT style="font-size:9.55pt"> &nbsp;</FONT>target<FONT style="font-size:9.35pt"> &nbsp;</FONT>the<FONT style="font-size:9.45pt"> &nbsp;</FONT>cytoskeleton<FONT style="font-size:9.25pt"> &nbsp;</FONT>are<FONT style="font-size:9.25pt"> &nbsp;</FONT>highly<FONT style="font-size:9.3pt"> &nbsp;</FONT>effective<FONT style="font-size:9.3pt"> &nbsp;</FONT>anti-cancer<FONT style="font-size:9.5pt"> &nbsp;</FONT>drugs,<FONT style="font-size:9.25pt"> &nbsp;</FONT>mainly<FONT style="font-size:9.55pt"> &nbsp;</FONT>because</P>
<P style="margin-top:3.2px; margin-bottom:0px; font-family:Calibri,Times New Roman; font-size:11pt">they<FONT style="font-size:6.65pt"> &nbsp;</FONT>block<FONT style="font-size:6.45pt"> &nbsp;</FONT>the<FONT style="font-size:6.6pt"> &nbsp;</FONT>ability<FONT style="font-size:6.4pt"> &nbsp;</FONT>of<FONT style="font-size:6.55pt"> &nbsp;</FONT>the<FONT style="font-size:6.65pt"> &nbsp;</FONT>cytoskeleton<FONT style="font-size:6.25pt"> &nbsp;</FONT>to<FONT style="font-size:6.5pt"> &nbsp;</FONT>prepare<FONT style="font-size:6.35pt"> &nbsp;</FONT>the<FONT style="font-size:6.6pt"> &nbsp;</FONT>cell<FONT style="font-size:6.55pt"> &nbsp;</FONT>for<FONT style="font-size:6.55pt"> &nbsp;</FONT>division.<FONT style="font-size:6.55pt"> &nbsp;</FONT>After<FONT style="font-size:6.55pt"> &nbsp;</FONT>four<FONT style="font-size:6.55pt"> &nbsp;</FONT>decades</P>
<P style="margin-top:3.2px; margin-bottom:0px; font-family:Calibri,Times New Roman; font-size:11pt">they<FONT style="font-size:8pt"> &nbsp;</FONT>still<FONT style="font-size:8.15pt"> &nbsp;</FONT>remain<FONT style="font-size:8.1pt"> &nbsp;</FONT>among<FONT style="font-size:7.85pt"> &nbsp;</FONT>the<FONT style="font-size:7.95pt"> &nbsp;</FONT>most<FONT style="font-size:7.95pt"> &nbsp;</FONT>commonly<FONT style="font-size:8.6pt"> &nbsp;</FONT>prescribed<FONT style="font-size:8.2pt"> &nbsp;</FONT>chemotherapeutics.<FONT style="font-size:8pt"> &nbsp;</FONT>These<FONT style="font-size:8.3pt"> &nbsp;</FONT>include</P>
<P style="margin-top:3.2px; margin-bottom:0px; font-family:Calibri,Times New Roman; font-size:11pt">the<FONT style="font-size:7.95pt"> &nbsp;</FONT>taxanes<FONT style="font-size:7.65pt"> &nbsp;</FONT>(paclitaxel,<FONT style="font-size:7.6pt"> &nbsp;</FONT>docetaxel)<FONT style="font-size:7.95pt"> &nbsp;</FONT>and<FONT style="font-size:7.55pt"> &nbsp;</FONT>the<FONT style="font-size:7.65pt"> &nbsp;</FONT>vinca<FONT style="font-size:7.65pt"> &nbsp;</FONT>alkaloids<FONT style="font-size:7.9pt"> &nbsp;</FONT>(vincristine,<FONT style="font-size:7.65pt"> &nbsp;</FONT>vinblastine).<FONT style="font-size:8.45pt"> &nbsp;</FONT>Despite</P>
<P style="margin-top:3px; margin-bottom:0px; font-family:Calibri,Times New Roman; font-size:11pt">their &nbsp;common &nbsp;use &nbsp;and &nbsp;relative &nbsp;effectiveness, &nbsp;they &nbsp;bear &nbsp;a &nbsp;number &nbsp;of &nbsp;negative &nbsp;features</P>
<P style="margin-top:3.2px; margin-bottom:0px; font-family:Calibri,Times New Roman; font-size:11pt">including<FONT style="font-size:7.3pt"> &nbsp;</FONT>(a)<FONT style="font-size:7.4pt"> &nbsp;</FONT>non-specific<FONT style="font-size:7.4pt"> &nbsp;</FONT>activity<FONT style="font-size:7.45pt"> &nbsp;</FONT>against<FONT style="font-size:7.45pt"> &nbsp;</FONT>the<FONT style="font-size:7.4pt"> &nbsp;</FONT>cytoskeleton<FONT style="font-size:7.05pt"> &nbsp;</FONT>of<FONT style="font-size:7.4pt"> &nbsp;</FONT>non-cancer<FONT style="font-size:7.4pt"> &nbsp;</FONT>cells<FONT style="font-size:7.4pt"> &nbsp;</FONT>resulting<FONT style="font-size:7.3pt"> &nbsp;</FONT>in<FONT style="font-size:7.25pt"> &nbsp;</FONT>a</P>
<P style="margin-top:3.2px; margin-bottom:0px; font-family:Calibri,Times New Roman; font-size:11pt">range<FONT style="font-size:8.25pt"> &nbsp;</FONT>of<FONT style="font-size:7.9pt"> &nbsp;</FONT>serious<FONT style="font-size:7.9pt"> &nbsp;</FONT>side-effects,<FONT style="font-size:8.25pt"> &nbsp;</FONT>(b)<FONT style="font-size:7.9pt"> &nbsp;</FONT>limited<FONT style="font-size:7.95pt"> &nbsp;</FONT>or<FONT style="font-size:7.9pt"> &nbsp;</FONT>no<FONT style="font-size:8.1pt"> &nbsp;</FONT>effectiveness<FONT style="font-size:7.95pt"> &nbsp;</FONT>against<FONT style="font-size:7.7pt"> &nbsp;</FONT>many<FONT style="font-size:8pt"> &nbsp;</FONT>types<FONT style="font-size:7.95pt"> &nbsp;</FONT>of<FONT style="font-size:7.9pt"> &nbsp;</FONT>cancer,</P>
<P style="margin-top:3.2px; margin-bottom:0px; font-family:Calibri,Times New Roman; font-size:11pt">and &nbsp;(c) &nbsp;the<FONT style="font-size:9.8pt"> &nbsp;</FONT>rapid &nbsp;ability<FONT style="font-size:9.85pt"> &nbsp;</FONT>of &nbsp;the &nbsp;cancer &nbsp;cell &nbsp;to &nbsp;develop &nbsp;resistance.<FONT style="font-size:9.75pt"> &nbsp;</FONT>The &nbsp;taxanes &nbsp;and &nbsp;vinca</P>
<P style="margin-top:3.2px; margin-bottom:0px; font-family:Calibri,Times New Roman; font-size:11pt">alkaloids are both off-patent.</P>
<P style="margin-top:21.067px; margin-bottom:0px; font-family:Calibri,Times New Roman; font-size:11pt">The<FONT style="font-size:6.6pt"> &nbsp;</FONT>taxanes<FONT style="font-size:6.3pt"> &nbsp;</FONT>and<FONT style="font-size:6.25pt"> &nbsp;</FONT>vinca<FONT style="font-size:6.35pt"> &nbsp;</FONT>alkaloids<FONT style="font-size:6.35pt"> &nbsp;</FONT>target<FONT style="font-size:6.5pt"> &nbsp;</FONT>that<FONT style="font-size:6.35pt"> &nbsp;</FONT>part<FONT style="font-size:6.05pt"> &nbsp;</FONT>of<FONT style="font-size:6.3pt"> &nbsp;</FONT>the<FONT style="font-size:6.6pt"> &nbsp;</FONT>cytoskeleton<FONT style="font-size:6.25pt"> &nbsp;</FONT>known<FONT style="font-size:6.55pt"> &nbsp;</FONT>as<FONT style="font-size:6.05pt"> &nbsp;</FONT>microtubules.</P>
<P style="margin-top:3.2px; margin-bottom:0px; font-family:Calibri,Times New Roman; font-size:11pt">There<FONT style="font-size:8.5pt"> &nbsp;</FONT>is<FONT style="font-size:8.4pt"> &nbsp;</FONT>a<FONT style="font-size:8.45pt"> &nbsp;</FONT>second<FONT style="font-size:8.4pt"> &nbsp;</FONT>component<FONT style="font-size:8.45pt"> &nbsp;</FONT>of<FONT style="font-size:8.45pt"> &nbsp;</FONT>the<FONT style="font-size:8.45pt"> &nbsp;</FONT>cytoskeleton<FONT style="font-size:8.4pt"> &nbsp;</FONT>that,<FONT style="font-size:8.45pt"> &nbsp;</FONT>while<FONT style="font-size:8.5pt"> &nbsp;</FONT>an<FONT style="font-size:8.35pt"> &nbsp;</FONT>obvious<FONT style="font-size:8.45pt"> &nbsp;</FONT>anti-cancer<FONT style="font-size:8.5pt"> &nbsp;</FONT>drug</P>
<P style="margin-top:3.2px; margin-bottom:0px; font-family:Calibri,Times New Roman; font-size:11pt">target, &nbsp;&nbsp;has &nbsp;&nbsp;to &nbsp;&nbsp;date &nbsp;&nbsp;successfully &nbsp;&nbsp;resisted &nbsp;&nbsp;drug &nbsp;&nbsp;development. &nbsp;&nbsp;That &nbsp;&nbsp;component &nbsp;&nbsp;is &nbsp;&nbsp;the</P>
<P style="margin-top:3.2px; margin-bottom:0px; font-family:Calibri,Times New Roman; font-size:11pt">microfilament,<FONT style="font-size:7.65pt"> &nbsp;</FONT>a<FONT style="font-size:7.6pt"> &nbsp;</FONT>series<FONT style="font-size:7.4pt"> &nbsp;</FONT>of<FONT style="font-size:7.4pt"> &nbsp;</FONT>filaments<FONT style="font-size:7.4pt"> &nbsp;</FONT>made<FONT style="font-size:7.7pt"> &nbsp;</FONT>up<FONT style="font-size:7.3pt"> &nbsp;</FONT>of<FONT style="font-size:7.65pt"> &nbsp;</FONT>inter-woven<FONT style="font-size:7.55pt"> &nbsp;</FONT>strands<FONT style="font-size:7.4pt"> &nbsp;</FONT>of<FONT style="font-size:7.65pt"> &nbsp;</FONT>two<FONT style="font-size:7.8pt"> &nbsp;</FONT>proteins,<FONT style="font-size:7.65pt"> &nbsp;</FONT>actin</P>
<P style="margin-top:3px; margin-bottom:0px; font-family:Calibri,Times New Roman; font-size:11pt">and tropomyosin. Drugs<FONT style="font-size:6.05pt"> &nbsp;</FONT>directed against<FONT style="font-size:6.1pt"> &nbsp;</FONT>the microfilaments<FONT style="font-size:6.05pt"> &nbsp;</FONT>have<FONT style="font-size:6.1pt"> &nbsp;</FONT>been too toxic<FONT style="font-size:6.1pt"> &nbsp;</FONT>to consider</P>
<P style="margin-top:3.2px; margin-bottom:0px; font-family:Calibri,Times New Roman; font-size:11pt">using<FONT style="font-size:7.55pt"> &nbsp;</FONT>because<FONT style="font-size:7.4pt"> &nbsp;</FONT>of<FONT style="font-size:7.35pt"> &nbsp;</FONT>the<FONT style="font-size:7.4pt"> &nbsp;</FONT>key<FONT style="font-size:7.7pt"> &nbsp;</FONT>role<FONT style="font-size:7.4pt"> &nbsp;</FONT>of<FONT style="font-size:7.35pt"> &nbsp;</FONT>microfilaments<FONT style="font-size:7.65pt"> &nbsp;</FONT>in<FONT style="font-size:7.25pt"> &nbsp;</FONT>muscle<FONT style="font-size:8.25pt"> &nbsp;</FONT>contraction,<FONT style="font-size:7.4pt"> &nbsp;</FONT>with<FONT style="font-size:7.5pt"> &nbsp;</FONT>muscle<FONT style="font-size:7.7pt"> &nbsp;</FONT>cells<FONT style="font-size:7.35pt"> &nbsp;</FONT>in</P>
<P style="margin-top:3.2px; margin-bottom:0px; font-family:Calibri,Times New Roman; font-size:11pt">the diaphragm and the heart being adversely affected.</P>
<P style="margin-top:21.067px; margin-bottom:0px; font-family:Calibri,Times New Roman; font-size:11pt">This roadblock<FONT style="font-size:6.2pt"> &nbsp;</FONT>has<FONT style="font-size:6.05pt"> &nbsp;</FONT>been overcome with two<FONT style="font-size:6.2pt"> &nbsp;</FONT>breakthroughs<FONT style="font-size:6.1pt"> &nbsp;</FONT>by<FONT style="font-size:6.25pt"> &nbsp;</FONT>Australian scientists<FONT style="font-size:6.25pt"> &nbsp;</FONT>in recent</P>
<P style="margin-top:3.2px; margin-bottom:0px; font-family:Calibri,Times New Roman; font-size:11pt">years.<FONT style="font-size:7.6pt"> &nbsp;</FONT>The<FONT style="font-size:7.7pt"> &nbsp;</FONT>first<FONT style="font-size:7.7pt"> &nbsp;</FONT>is<FONT style="font-size:7.6pt"> &nbsp;</FONT>that<FONT style="font-size:7.6pt"> &nbsp;</FONT>tropomyosins<FONT style="font-size:7.65pt"> &nbsp;</FONT>are<FONT style="font-size:7.65pt"> &nbsp;</FONT>distinguishable<FONT style="font-size:7.65pt"> &nbsp;</FONT>as<FONT style="font-size:7.65pt"> &nbsp;</FONT>muscle<FONT style="font-size:7.7pt"> &nbsp;</FONT>or<FONT style="font-size:7.6pt"> &nbsp;</FONT>non-muscle<FONT style="font-size:7.65pt"> &nbsp;</FONT>varieties.</P>
<P style="margin-top:3.2px; margin-bottom:0px; font-family:Calibri,Times New Roman; font-size:11pt">The<FONT style="font-size:7.95pt"> &nbsp;</FONT>second<FONT style="font-size:7.85pt"> &nbsp;</FONT>is<FONT style="font-size:7.9pt"> &nbsp;</FONT>that<FONT style="font-size:7.9pt"> &nbsp;</FONT>one<FONT style="font-size:7.95pt"> &nbsp;</FONT>particular<FONT style="font-size:7.8pt"> &nbsp;</FONT>form<FONT style="font-size:8pt"> &nbsp;</FONT>of<FONT style="font-size:7.9pt"> &nbsp;</FONT>non-muscle<FONT style="font-size:7.95pt"> &nbsp;</FONT>tropomyosin,<FONT style="font-size:7.9pt"> &nbsp;</FONT>known<FONT style="font-size:7.9pt"> &nbsp;</FONT>as<FONT style="font-size:7.65pt"> &nbsp;</FONT>Tm5NM1,<FONT style="font-size:8.3pt"> &nbsp;</FONT>is</P>
<P style="margin-top:3.2px; margin-bottom:0px; font-family:Calibri,Times New Roman; font-size:11pt">restricted largely to cancer cells and is critical to the survival of the cancer cell.</P>
<P style="margin-top:21.067px; margin-bottom:0px; font-family:Calibri,Times New Roman; font-size:11pt">The<FONT style="font-size:6.6pt"> &nbsp;</FONT>private<FONT style="font-size:6.65pt"> &nbsp;</FONT>Australian<FONT style="font-size:6.55pt"> &nbsp;</FONT>biotechnology<FONT style="font-size:6.65pt"> &nbsp;</FONT>company,<FONT style="font-size:6.6pt"> &nbsp;</FONT>Genscreen<FONT style="font-size:6.5pt"> &nbsp;</FONT>Pty<FONT style="font-size:6.7pt"> &nbsp;</FONT>Ltd,<FONT style="font-size:6.6pt"> &nbsp;</FONT>has<FONT style="font-size:6.55pt"> &nbsp;</FONT>developed<FONT style="font-size:6.55pt"> &nbsp;</FONT>extensive</P>
<P style="margin-top:3px; margin-bottom:0px; font-family:Calibri,Times New Roman; font-size:11pt">intellectual<FONT style="font-size:7.6pt"> &nbsp;</FONT>property<FONT style="font-size:7.8pt"> &nbsp;</FONT>in<FONT style="font-size:7.5pt"> &nbsp;</FONT>the<FONT style="font-size:7.95pt"> &nbsp;</FONT>field<FONT style="font-size:7.5pt"> &nbsp;</FONT>of<FONT style="font-size:7.6pt"> &nbsp;</FONT>drug<FONT style="font-size:7.8pt"> &nbsp;</FONT>design<FONT style="font-size:7.55pt"> &nbsp;</FONT>targeting<FONT style="font-size:7.8pt"> &nbsp;</FONT>the<FONT style="font-size:7.65pt"> &nbsp;</FONT>Tm5NM1<FONT style="font-size:8pt"> &nbsp;</FONT>protein.<FONT style="font-size:7.85pt"> &nbsp;</FONT>Laboratory</P>
<P style="margin-top:3.2px; margin-bottom:0px; font-family:Calibri,Times New Roman; font-size:11pt">and<FONT style="font-size:9.7pt"> &nbsp;</FONT>animal<FONT style="font-size:9.7pt"> &nbsp;</FONT>studies<FONT style="font-size:9.8pt"> &nbsp;</FONT>have<FONT style="font-size:9.8pt"> &nbsp;</FONT>confirmed<FONT style="font-size:9.75pt"> &nbsp;</FONT>the<FONT style="font-size:9.8pt"> &nbsp;</FONT>anti-cancer<FONT style="font-size:9.55pt"> &nbsp;</FONT>effect<FONT style="font-size:9.8pt"> &nbsp;</FONT>and<FONT style="font-size:9.7pt"> &nbsp;</FONT>safety<FONT style="font-size:9.85pt"> &nbsp;</FONT>of<FONT style="font-size:9.5pt"> &nbsp;</FONT>this<FONT style="font-size:9.55pt"> &nbsp;</FONT>drug<FONT style="font-size:9.65pt"> &nbsp;</FONT>target.</P>
<P style="margin-top:3.2px; margin-bottom:0px; font-family:Calibri,Times New Roman; font-size:11pt">Novogen<FONT style="font-size:8.15pt"> &nbsp;</FONT>has<FONT style="font-size:7.9pt"> &nbsp;</FONT>acquired<FONT style="font-size:7.8pt"> &nbsp;</FONT>the<FONT style="font-size:7.95pt"> &nbsp;</FONT>technology<FONT style="font-size:8.25pt"> &nbsp;</FONT>from<FONT style="font-size:8.3pt"> &nbsp;</FONT>Genscreen<FONT style="font-size:8.5pt"> &nbsp;</FONT>in<FONT style="font-size:8.05pt"> &nbsp;</FONT>a<FONT style="font-size:7.9pt"> &nbsp;</FONT>transaction<FONT style="font-size:8.2pt"> &nbsp;</FONT>based<FONT style="font-size:7.85pt"> &nbsp;</FONT>on<FONT style="font-size:8.1pt"> &nbsp;</FONT>a<FONT style="font-size:8.15pt"> &nbsp;</FONT>royalty</P>
<P style="margin-top:3.2px; margin-bottom:0px; font-family:Calibri,Times New Roman; font-size:11pt">payment of product sales, with no upfront or milestone fees.</P>
<P style="margin-top:3.2px; margin-bottom:0px"><BR>
<BR></P>
<P style="margin-top:117.4px; margin-bottom:0px; font-family:Calibri,Times New Roman; font-size:11pt; page-break-before:always">&quot;This &nbsp;&nbsp;&nbsp;anti-tropomyosin &nbsp;&nbsp;&nbsp;drug &nbsp;&nbsp;&nbsp;technology &nbsp;&nbsp;&nbsp;perfectly &nbsp;&nbsp;&nbsp;complements &nbsp;&nbsp;&nbsp;Novogen<font style='font-family:Arial Unicode MS,Times New Roman'>&#8217;</font>s &nbsp;&nbsp;&nbsp;super-</P>
<P style="margin-top:3.2px; margin-bottom:0px; font-family:Calibri,Times New Roman; font-size:11pt">benzopyran<FONT style="font-size:9.25pt"> &nbsp;&nbsp;</FONT>drug<FONT style="font-size:9.25pt"> &nbsp;&nbsp;</FONT>technology<FONT style="font-size:9.4pt"> &nbsp;&nbsp;</FONT>in<FONT style="font-size:9.25pt"> &nbsp;&nbsp;</FONT>our<FONT style="font-size:9.5pt"> &nbsp;&nbsp;</FONT>quest<FONT style="font-size:9.35pt"> &nbsp;&nbsp;</FONT>to<FONT style="font-size:9.5pt"> &nbsp;&nbsp;</FONT>deliver<FONT style="font-size:9.35pt"> &nbsp;&nbsp;</FONT>comprehensive<FONT style="font-size:9.35pt"> &nbsp;&nbsp;</FONT>anti-cancer<FONT style="font-size:9.35pt"> &nbsp;&nbsp;</FONT>drug</P>
<P style="margin-top:3.2px; margin-bottom:0px; font-family:Calibri,Times New Roman; font-size:11pt">therapy. Our super-benzopyran family of drugs are highly effective against cancer stem cells,</P>
<P style="margin-top:3.2px; margin-bottom:0px; font-family:Calibri,Times New Roman; font-size:11pt">a<FONT style="font-size:7.9pt"> &nbsp;&nbsp;</FONT>basic<FONT style="font-size:7.9pt"> &nbsp;&nbsp;</FONT>requirement<FONT style="font-size:7.95pt"> &nbsp;&nbsp;</FONT>of<FONT style="font-size:7.75pt"> &nbsp;&nbsp;</FONT>successful<FONT style="font-size:8.1pt"> &nbsp;&nbsp;</FONT>longer<FONT style="font-size:7.95pt"> &nbsp;&nbsp;</FONT>term<FONT style="font-size:7.95pt"> &nbsp;&nbsp;</FONT>cancer<FONT style="font-size:7.95pt"> &nbsp;&nbsp;</FONT>therapy,<font style='font-family:Arial Unicode MS,Times New Roman'>&#8221;</font><FONT style="font-size:7.85pt"> &nbsp;&nbsp;</FONT>said<FONT style="font-size:7.85pt"> &nbsp;&nbsp;</FONT>Novogen<FONT style="font-size:7.9pt"> &nbsp;&nbsp;</FONT>CEO,<FONT style="font-size:7.75pt"> &nbsp;&nbsp;</FONT>Dr</P>
<P style="margin-top:3px; margin-bottom:0px; font-family:Calibri,Times New Roman; font-size:11pt">Graham Kelly.</P>
<P style="margin-top:21.067px; margin-bottom:0px; font-family:Calibri,Times New Roman; font-size:11pt"><font style='font-family:Arial Unicode MS,Times New Roman'>&#8220;</font>But<FONT style="font-size:6.35pt"> &nbsp;</FONT>we<FONT style="font-size:6.4pt"> &nbsp;</FONT>still<FONT style="font-size:6.5pt"> &nbsp;</FONT>need<FONT style="font-size:6.55pt"> &nbsp;</FONT>to<FONT style="font-size:6.45pt"> &nbsp;</FONT>eliminate<FONT style="font-size:6.65pt"> &nbsp;</FONT>all<FONT style="font-size:6.25pt"> &nbsp;</FONT>cancer<FONT style="font-size:6.35pt"> &nbsp;</FONT>cells<FONT style="font-size:6.35pt"> &nbsp;</FONT>and<FONT style="font-size:6.5pt"> &nbsp;</FONT>that<FONT style="font-size:6.6pt"> &nbsp;</FONT>is<FONT style="font-size:6.75pt"> &nbsp;</FONT>where<FONT style="font-size:6.35pt"> &nbsp;</FONT>the<FONT style="font-size:6.35pt"> &nbsp;</FONT>potential<FONT style="font-size:6.65pt"> &nbsp;</FONT>potency<FONT style="font-size:6.4pt"> &nbsp;</FONT>of<FONT style="font-size:6.55pt"> &nbsp;</FONT>an</P>
<P style="margin-top:3.2px; margin-bottom:0px; font-family:Calibri,Times New Roman; font-size:11pt">anti-tropomyosin<FONT style="font-size:7pt"> &nbsp;</FONT>drug<FONT style="font-size:7.2pt"> &nbsp;</FONT>comes<FONT style="font-size:6.9pt"> &nbsp;</FONT>in.<FONT style="font-size:7.05pt"> &nbsp;</FONT>Rather<FONT style="font-size:7.15pt"> &nbsp;</FONT>than<FONT style="font-size:6.7pt"> &nbsp;</FONT>relying<FONT style="font-size:7pt"> &nbsp;</FONT>on<FONT style="font-size:7.05pt"> &nbsp;</FONT>a<FONT style="font-size:6.8pt"> &nbsp;</FONT>blend<FONT style="font-size:6.8pt"> &nbsp;</FONT>of<FONT style="font-size:7.1pt"> &nbsp;</FONT>super-benzopyran<FONT style="font-size:7pt"> &nbsp;</FONT>drugs</P>
<P style="margin-top:3.2px; margin-bottom:0px; font-family:Calibri,Times New Roman; font-size:11pt">and<FONT style="font-size:7.85pt"> &nbsp;&nbsp;</FONT>currently<FONT style="font-size:7.75pt"> &nbsp;&nbsp;</FONT>available<FONT style="font-size:7.95pt"> &nbsp;&nbsp;</FONT>standard<FONT style="font-size:7.85pt"> &nbsp;&nbsp;</FONT>therapy<FONT style="font-size:7.8pt"> &nbsp;&nbsp;</FONT>to<FONT style="font-size:7.85pt"> &nbsp;&nbsp;</FONT>achieve<FONT style="font-size:7.95pt"> &nbsp;&nbsp;</FONT>across-the-board &nbsp;eradication &nbsp;of<FONT style="font-size:7.9pt"> &nbsp;&nbsp;</FONT>all</P>
<P style="margin-top:3.2px; margin-bottom:0px; font-family:Calibri,Times New Roman; font-size:11pt">cancer<FONT style="font-size:7.15pt"> &nbsp;</FONT>cells,<FONT style="font-size:7.15pt"> &nbsp;</FONT>the<FONT style="font-size:7.15pt"> &nbsp;</FONT>anti-Tm<FONT style="font-size:7.2pt"> &nbsp;</FONT>drugs<FONT style="font-size:7.15pt"> &nbsp;</FONT>now<FONT style="font-size:7.2pt"> &nbsp;</FONT>give<FONT style="font-size:7.15pt"> &nbsp;</FONT>us<FONT style="font-size:7.25pt"> &nbsp;</FONT>the<FONT style="font-size:6.85pt"> &nbsp;</FONT>opportunity<FONT style="font-size:7.2pt"> &nbsp;</FONT>to<FONT style="font-size:7.25pt"> &nbsp;</FONT>own<FONT style="font-size:7.1pt"> &nbsp;</FONT>the<FONT style="font-size:7.15pt"> &nbsp;</FONT>full<FONT style="font-size:7.05pt"> &nbsp;</FONT>complement<FONT style="font-size:6.85pt"> &nbsp;</FONT>of</P>
<P style="margin-top:3.2px; margin-bottom:0px; font-family:Calibri,Times New Roman; font-size:11pt">effective drugs, Kelly added&quot;</P>
<P style="margin-top:21.067px; margin-bottom:0px; font-family:Calibri,Times New Roman; font-size:11pt">Ian &nbsp;Dixon,<FONT style="font-size:7.75pt"> &nbsp;&nbsp;</FONT>CEO<FONT style="font-size:7.75pt"> &nbsp;&nbsp;</FONT>of &nbsp;Genscreen,<FONT style="font-size:7.75pt"> &nbsp;&nbsp;</FONT>said,<FONT style="font-size:7.75pt"> &nbsp;&nbsp;</FONT>&quot;we<FONT style="font-size:7.8pt"> &nbsp;&nbsp;</FONT>have<FONT style="font-size:7.75pt"> &nbsp;&nbsp;</FONT>always<FONT style="font-size:8.05pt"> &nbsp;&nbsp;</FONT>seen<FONT style="font-size:7.75pt"> &nbsp;&nbsp;</FONT>the<FONT style="font-size:7.8pt"> &nbsp;&nbsp;</FONT>anti-Tms<FONT style="font-size:7.85pt"> &nbsp;&nbsp;</FONT>as &nbsp;an &nbsp;obvious</P>
<P style="margin-top:3.2px; margin-bottom:0px; font-family:Calibri,Times New Roman; font-size:11pt">replacement<FONT style="font-size:7.95pt"> &nbsp;</FONT>for<FONT style="font-size:7.9pt"> &nbsp;</FONT>taxanes,<FONT style="font-size:7.65pt"> &nbsp;</FONT>one<FONT style="font-size:7.95pt"> &nbsp;</FONT>of<FONT style="font-size:7.9pt"> &nbsp;</FONT>the<FONT style="font-size:7.95pt"> &nbsp;</FONT>largest-selling<FONT style="font-size:7.8pt"> &nbsp;</FONT>class<FONT style="font-size:7.9pt"> &nbsp;</FONT>of<FONT style="font-size:7.9pt"> &nbsp;</FONT>anti-cancer<FONT style="font-size:7.95pt"> &nbsp;</FONT>drugs<FONT style="font-size:7.9pt"> &nbsp;</FONT>that<FONT style="font-size:7.9pt"> &nbsp;</FONT>are<FONT style="font-size:7.9pt"> &nbsp;</FONT>now</P>
<P style="margin-top:3px; margin-bottom:0px; font-family:Calibri,Times New Roman; font-size:11pt">off<FONT style="font-size:6.55pt"> &nbsp;</FONT>patent.<FONT style="font-size:6.65pt"> &nbsp;</FONT>But<FONT style="font-size:6.65pt"> &nbsp;</FONT>unlike<FONT style="font-size:6.7pt"> &nbsp;</FONT>the<FONT style="font-size:6.6pt"> &nbsp;</FONT>taxanes,<FONT style="font-size:6.55pt"> &nbsp;</FONT>we<FONT style="font-size:6.65pt"> &nbsp;</FONT>see<FONT style="font-size:6.65pt"> &nbsp;</FONT>the<FONT style="font-size:6.6pt"> &nbsp;</FONT>anti-Tms<FONT style="font-size:6.65pt"> &nbsp;</FONT>as<FONT style="font-size:6.55pt"> &nbsp;</FONT>having<FONT style="font-size:6.5pt"> &nbsp;</FONT>so<FONT style="font-size:6.45pt"> &nbsp;</FONT>much<FONT style="font-size:6.5pt"> &nbsp;</FONT>less<FONT style="font-size:6.35pt"> &nbsp;</FONT>toxicity,<FONT style="font-size:6.6pt"> &nbsp;</FONT>plus</P>
<P style="margin-top:3.2px; margin-bottom:0px; font-family:Calibri,Times New Roman; font-size:11pt">being<FONT style="font-size:8.1pt"> &nbsp;</FONT>more<FONT style="font-size:8.2pt"> &nbsp;</FONT>broadly<FONT style="font-size:8.25pt"> &nbsp;</FONT>active,<FONT style="font-size:8.2pt"> &nbsp;</FONT>including<FONT style="font-size:8.1pt"> &nbsp;</FONT>against<FONT style="font-size:8.25pt"> &nbsp;</FONT>cancers<FONT style="font-size:7.95pt"> &nbsp;</FONT>such<FONT style="font-size:8.05pt"> &nbsp;</FONT>as<FONT style="font-size:7.9pt"> &nbsp;</FONT>melanoma<FONT style="font-size:7.9pt"> &nbsp;</FONT>that<FONT style="font-size:7.9pt"> &nbsp;</FONT>taxanes<FONT style="font-size:8.15pt"> &nbsp;</FONT>have</P>
<P style="margin-top:3.2px; margin-bottom:0px; font-family:Calibri,Times New Roman; font-size:11pt">little<FONT style="font-size:6.05pt"> &nbsp;</FONT>effect against.<FONT style="font-size:6.15pt"> &nbsp;</FONT>We<FONT style="font-size:6.1pt"> &nbsp;</FONT>are pleased to<FONT style="font-size:6.2pt"> &nbsp;</FONT>put<FONT style="font-size:6.1pt"> &nbsp;</FONT>the<FONT style="font-size:6.1pt"> &nbsp;</FONT>technology<FONT style="font-size:6.15pt"> &nbsp;</FONT>into<FONT style="font-size:6.2pt"> &nbsp;</FONT>the<FONT style="font-size:6.1pt"> &nbsp;</FONT>hands<FONT style="font-size:6.05pt"> &nbsp;</FONT>of a Company<FONT style="font-size:6.05pt"> &nbsp;</FONT>with</P>
<P style="margin-top:3.2px; margin-bottom:0px; font-family:Calibri,Times New Roman; font-size:11pt">the enthusiasm and expertise to see its potential realised.&quot;</P>
<P style="margin-top:21.067px; margin-bottom:0px; font-family:Calibri,Times New Roman; font-size:11pt">Novogen<FONT style="font-size:8.1pt"> &nbsp;&nbsp;</FONT>will<FONT style="font-size:8.25pt"> &nbsp;&nbsp;</FONT>undertake<FONT style="font-size:8.2pt"> &nbsp;&nbsp;</FONT>a<FONT style="font-size:8.3pt"> &nbsp;&nbsp;</FONT>program<FONT style="font-size:8.35pt"> &nbsp;&nbsp;</FONT>to<FONT style="font-size:8.35pt"> &nbsp;&nbsp;</FONT>identify<FONT style="font-size:8.35pt"> &nbsp;&nbsp;</FONT>lead<FONT style="font-size:8.2pt"> &nbsp;&nbsp;</FONT>compounds,<FONT style="font-size:8.1pt"> &nbsp;&nbsp;</FONT>with<FONT style="font-size:8.25pt"> &nbsp;&nbsp;</FONT>prostate<FONT style="font-size:8.15pt"> &nbsp;&nbsp;</FONT>cancer,</P>
<P style="margin-top:3.2px; margin-bottom:0px; font-family:Calibri,Times New Roman; font-size:11pt">melanoma and neuroblastoma the nominal targets.</P>
<P style="margin-top:56.6px; margin-bottom:0px; font-family:Calibri,Times New Roman; font-size:11pt"><B>About Novogen</B></P>
<P style="margin-top:6.4px; margin-bottom:0px; font-family:Calibri,Times New Roman; font-size:11pt">Novogen<FONT style="font-size:7.1pt"> &nbsp;</FONT>Ltd<FONT style="font-size:7.1pt"> &nbsp;</FONT>is<FONT style="font-size:7.1pt"> &nbsp;</FONT>a<FONT style="font-size:7.1pt"> &nbsp;</FONT>public<FONT style="font-size:7.35pt"> &nbsp;</FONT>Australian<FONT style="font-size:7pt"> &nbsp;</FONT>biotechnology<FONT style="font-size:6.95pt"> &nbsp;</FONT>company<FONT style="font-size:7.2pt"> &nbsp;</FONT>whose<FONT style="font-size:7.2pt"> &nbsp;</FONT>shares<FONT style="font-size:7.2pt"> &nbsp;</FONT>trade<FONT style="font-size:6.9pt"> &nbsp;</FONT>on<FONT style="font-size:7.05pt"> &nbsp;</FONT>both<FONT style="font-size:7.1pt"> &nbsp;</FONT>the</P>
<P style="margin-top:6.4px; margin-bottom:0px; font-family:Calibri,Times New Roman; font-size:11pt">Australian<FONT style="font-size:8.1pt"> &nbsp;</FONT>Stock<FONT style="font-size:8.2pt"> &nbsp;</FONT>Exchange<FONT style="font-size:7.95pt"> &nbsp;</FONT>(symbol<FONT style="font-size:7.85pt"> &nbsp;</FONT><font style='font-family:Arial Unicode MS,Times New Roman'>&#8216;</font>NRT<font style='font-family:Arial Unicode MS,Times New Roman'>&#8217;</font>)<FONT style="font-size:8pt"> &nbsp;</FONT>and<FONT style="font-size:8.1pt"> &nbsp;</FONT>NASDAQ<FONT style="font-size:8.15pt"> &nbsp;</FONT>(symbol<FONT style="font-size:8.15pt"> &nbsp;</FONT><font style='font-family:Arial Unicode MS,Times New Roman'>&#8216;</font>NVGN<font style='font-family:Arial Unicode MS,Times New Roman'>&#8217;</font>). &nbsp;&nbsp;The<FONT style="font-size:7.95pt"> &nbsp;</FONT>Company<FONT style="font-size:8.25pt"> &nbsp;</FONT>is</P>
<P style="margin-top:6.2px; margin-bottom:0px; font-family:Calibri,Times New Roman; font-size:11pt">based<FONT style="font-size:6.3pt"> &nbsp;</FONT>in Sydney,<FONT style="font-size:6.35pt"> &nbsp;</FONT>Australia, with an office<FONT style="font-size:6.15pt"> &nbsp;</FONT>in<FONT style="font-size:6.2pt"> &nbsp;</FONT>Ithaca,<FONT style="font-size:6.05pt"> &nbsp;</FONT>NY,<FONT style="font-size:6.35pt"> &nbsp;</FONT>USA. The<FONT style="font-size:6.1pt"> &nbsp;</FONT>Company<FONT style="font-size:6.6pt"> &nbsp;</FONT>is focused on the</P>
<P style="margin-top:6.2px; margin-bottom:0px; font-family:Calibri,Times New Roman; font-size:11pt">development<FONT style="font-size:8.2pt"> &nbsp;</FONT>of<FONT style="font-size:8.5pt"> &nbsp;</FONT>drug<FONT style="font-size:8.35pt"> &nbsp;</FONT>strategies<FONT style="font-size:8.5pt"> &nbsp;</FONT>that<FONT style="font-size:8.2pt"> &nbsp;</FONT>will<FONT style="font-size:8.4pt"> &nbsp;</FONT>deliver<FONT style="font-size:8.45pt"> &nbsp;</FONT>personalized<FONT style="font-size:8.45pt"> &nbsp;</FONT>chemotherapy<FONT style="font-size:8.5pt"> &nbsp;</FONT>based<FONT style="font-size:8.45pt"> &nbsp;</FONT>on<FONT style="font-size:8.4pt"> &nbsp;</FONT>the</P>
<P style="margin-top:6.2px; margin-bottom:0px; font-family:Calibri,Times New Roman; font-size:11pt">effective<FONT style="font-size:8.5pt"> &nbsp;&nbsp;</FONT>elimination<FONT style="font-size:8.4pt"> &nbsp;&nbsp;</FONT>of<FONT style="font-size:8.6pt"> &nbsp;&nbsp;</FONT>cancer<FONT style="font-size:8.65pt"> &nbsp;&nbsp;</FONT>stem<FONT style="font-size:8.7pt"> &nbsp;&nbsp;</FONT>cells<FONT style="font-size:8.6pt"> &nbsp;&nbsp;</FONT>and<FONT style="font-size:8.4pt"> &nbsp;&nbsp;</FONT>somatic<FONT style="font-size:8.45pt"> &nbsp;&nbsp;</FONT>cancer<FONT style="font-size:8.65pt"> &nbsp;&nbsp;</FONT>cells<FONT style="font-size:8.6pt"> &nbsp;&nbsp;</FONT>across<FONT style="font-size:8.45pt"> &nbsp;&nbsp;</FONT>a<FONT style="font-size:8.6pt"> &nbsp;&nbsp;</FONT>range<FONT style="font-size:8.5pt"> &nbsp;&nbsp;</FONT>of</P>
<P style="margin-top:6.4px; margin-bottom:0px; font-family:Calibri,Times New Roman; font-size:11pt">genotypes.</P>
<P style="margin-top:27.867px; margin-bottom:0px; font-family:Calibri,Times New Roman; font-size:11pt"><B>Further information</B></P>
<P style="margin-top:6.4px; margin-bottom:0px; font-family:Calibri,Times New Roman; font-size:11pt">Contact Dr Graham Kelly, Chief Executive Officer.</P>
<P style="margin-top:27.867px; margin-bottom:0px; font-family:Calibri,Times New Roman; font-size:11pt">Tel: 61 2 9476 0344</P>
<P style="margin-top:3.2px; margin-bottom:0px; font-family:Calibri,Times New Roman; font-size:11pt">Fax: 61 2 9476 0388</P>
<P style="margin-top:3.2px; margin-bottom:0px; font-family:Calibri,Times New Roman; font-size:11pt">Mobile: (61) 0429 854 390</P>
<P style="margin-top:21.067px; margin-bottom:0px; font-family:Calibri,Times New Roman; font-size:11pt">16-20 Edgeworth David Ave &nbsp;Hornsby &nbsp;NSW 2077 &nbsp;AUSTRALIA</P>
<P style="margin-top:3.2px; margin-bottom:0px; font-family:Calibri,Times New Roman; font-size:11pt">PO Box 2333 Hornsby Westfield &nbsp;NSW &nbsp;1635 &nbsp;&nbsp;AUSTRALIA</P>
<P style="margin-top:21.067px; margin-bottom:0px; font-family:Calibri,Times New Roman; font-size:11pt">Email: Graham.Kelly@novogen.com</P>
<P style="margin-top:24.2px; margin-bottom:0px; font-family:Calibri,Times New Roman; font-size:11pt">Further information is available on the Company<font style='font-family:Arial Unicode MS,Times New Roman'>&#8217;</font>s web site, www.novogen.com</P>
<P style="margin-top:24.2px; margin-bottom:0px"><BR>
<BR></P>
</DIV></BODY>
<!-- EDGAR Validation Code: DA130191 -->
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>asxannouncement1a1310id001.jpg
<DESCRIPTION>IMAGE
<TEXT>
begin 644 asxannouncement1a1310id001.jpg
M_]C_X``02D9)1@`!`0$```````#_X0"N17AI9@``34T`*@````@``8=I``0`
M```!````&@```````9*&``<```!Z````+`````!53DE#3T1%``!#`%(`10!!
M`%0`3P!2`#H`(`!G`&0`+0!J`'``90!G`"``=@`Q`"X`,``@`"@`=0!S`&D`
M;@!G`"``20!*`$<`(`!*`%``10!'`"``=@`V`#(`*0`L`"``<0!U`&$`;`!I
M`'0`>0`@`#T`(``Y`#``"O_^`#Q#4D5!5$]2.B!G9"UJ<&5G('8Q+C`@*'5S
M:6YG($E*1R!*4$5'('8V,BDL('%U86QI='D@/2`Y,`H`_]L`0P`(!@8'!@4(
M!P<'"0D("@P4#0P+"PP9$A,/%!T:'QX=&AP<("0N)R`B+",<'"@W*2PP,30T
M-!\G.3TX,CPN,S0R_]L`0P$)"0D,"PP8#0T8,B$<(3(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R_\``$0@`@`/H
M`P$B``(1`0,1`?_$`!\```$%`0$!`0$!```````````!`@,$!08'"`D*"__$
M`+40``(!`P,"!`,%!00$```!?0$"`P`$$042(3%!!A-180<B<10R@9&A""-"
ML<$54M'P)#-B<H()"A87&!D:)28G*"DJ-#4V-S@Y.D-$149'2$E*4U155E=8
M65IC9&5F9VAI:G-T=79W>'EZ@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JR
ML[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KAXN/DY>;GZ.GJ\?+S]/7V]_CY
M^O_$`!\!``,!`0$!`0$!`0$````````!`@,$!08'"`D*"__$`+41``(!`@0$
M`P0'!00$``$"=P`!`@,1!`4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)R
MT0H6)#3A)?$7&!D:)B<H*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H
M:6IS='5V=WAY>H*#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BY
MNL+#Q,7&Q\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:``P#`0`"
M$0,1`#\`]_HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BD)P.E-
M4[E!(QF@!]%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%
M%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444
M`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`
M4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1
M110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%
M%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`P\"L?PUJ@U;0+2Y)S)M,
M<O'1T)5OU4UL,.#7BO@GQ6/#?C'5=$OY`EE<7LFQFX$4NXCGT!`'TQ515T8U
M*O))7V9[92TP-FGU)L%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110
M`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!
M1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%
M%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`444
M4`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110
M`4444`%%%%`!1110`G:@T57N+J*UA,L\B1H#@L[8'YT!UL6**J6NHVEX6%M<
M13;>6\MPV/RJWFD-IK<*6FY[U5@U&SNW*6US#,RC)".&(%,6Y<HIN[VI"W?M
M0`XT=JR[W7]*T]REUJ%M#(!G:\H!_*HK;Q3H=VVRWU2U=CT`E&:7,BU2FU=)
MFN>017S)XZL_L?CC686R0UP9>?\`;^;^M?3`?(R.]>$?&&P-KXPAO`"$N[93
MG/&Y3M/Z;?SK6D]3S\=!^SOV-OX;_$,@P:%K4QS]RUN7/7_88^OH:]?#9%?(
M>>_ZU[M\,?&K:W:_V3J$F=1M4^5R>9HQQD_[0XS^!JJD.J,L)B;^Y(])HIN?
M:ES6)Z0>]%4_[1LQ<BV-S")R<"/S!NSUZ5:W>U`VFMQWUI*J7>J6=@FZ[N8H
M5]9'`%9J^,?#SOL75[0M_P!=12ND4J<Y*Z3-ZEJO#<Q7,8DAD21&'#*V0:E!
MS3(::W'T4F>*:7`')%`#J*Q[GQ/HMFY2XU.UC<=5,HR/PH@\4Z'<L%BU6T=C
MT`E%+F1I[*I:]F;-%1)(L@!4@@]"#3F8*I9B`!U)-!G;4=16;_;VE=]1M!S_
M`,]E_P`:7^W=*_Z"-I_W^7_&BZ*Y)=C1HJG;:G97CLEM=0S,HR1'(&('X5/-
M/'!$TLKI'&HRS.<`?C3N*S3L2T53MM2L[MREO<PS,.2$D!(%6\TMP::W%I::
M>G/:JD&I6=S.T$-U!)(O5$D!8?A0))LNT444P"BBB@`HHHH`****`"BBB@`H
MHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BB
MB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****
M`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`
M****`"BBB@`HHHH`****`"BBB@`H[444`-KC/B<!_P`(1==_F3_T(5VE<9\3
MO^1)N_\`>3_T(5$_A9OA?XT?4\J\-ZI=>%=2L]6"_P"AW!9)`O\`&H.&_P"!
M#&:]_M;F*[MH[B!@\<BAE8'@@CBO+_#OAV/Q'\,VMP%6XCFE>!\?=?<?Y]*?
M\,O$4EO/+X<U#]W(C-Y"OU!!^9/PZC\:RIMQLF>AC8JMS2CO'?T/4I?]6P]J
M\A^$H`\0ZHP')AYX']\UZXY)4_2O)/A+_P`C#JG_`%Q'_H9K2?Q(Y*"_<U/D
M>OG`ZUY/XU\<WMUJ+:'H3.#O\IY8AEW?^XG^-=]XKU-])\,:A>QG$D<)V'_:
MZ#]:\]^$^BQSW5UJ\PW&']S$2/XCRS?7I^M*;N^4O"TXQIRK35[;>I8T7X4K
M,@N-;NY3*_S&*(]#_M,?F)_*KFI_"73I82VF7<]O,!\HD.]2?YC\#7I&.*,<
M=J?LHF3QM9RO<\5T/Q1JW@K6/[)UG?):*0'0G<8P?XT)ZK70_%K2UU;PC!JM
MOMD-FXDW@\&)^&(_\=/X5:^*6C177A\:DJ?O[-\[AU*,<,/US^%+\.ITUOP-
M+IMYB1(B]JZGNA'`_(X_"BG)PG8O&THXG#^VBK/9G@./6KFEZE<Z1J=OJ-FV
MV>W<.GH?8_49'XFK7B'1)_#FNW6F7'WHFRCXXD0_=;^GX&LFO0^)'Q[4J<O0
M^KM&U*#5])M-0MCF*XC$B\],]1^!XJQ=W"6MK+/(V%C0LQ/8"O,O@QK!N-(O
M=)D;)M9!+%SSL?J/^^@Q_P"!5N_$_5_[.\+26ZOMEO&\D8/(7JQ_[Y!KCJ>[
M<^CP?[]Q2ZG+?#ZV;Q!XUU#Q#/&"(V+H2/XFX7\E_G76>.O&8\.6Z6UKL;49
MU^3=TC7NYJ;X?:3_`&3X3MVD3;/<YGE'NW0?@H`KSFWC_P"$R^)LGV@E[9IV
M8CMY4?`'XX'_`'T:PNU%+JSU8QA5KRE)>[$N:#X'U/Q?C5M:OIDAE^9"XS(X
M]@>%7TXKJ)OA-H;6^R.:[CD'\?F[OT(Q^0KO%C5%4(`JCH`.*DQ5JFEN<U3&
MU7*\79=CPV[L?$'PWU&.6WN#)8R-A2`?+D_V67^%L>E>L>&]>MO$.CQ7]O\`
M*3Q)&3RC]Q4VMZ5!K&D75C<#='*A'/\`">Q'T/->7?"Z\GT_Q/=Z3*Q_>HV]
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MNO\`KDW\JIJR,>9SJ<S/$/`O@ZR\5&^^TSS0&WV;?)V\[MV<Y!]*[+_A3VD?
M]!&^_P#(?_Q%9WP?=8WU;<0,^5C/']^O53+&!]]?SK.$8M'H8O$5H56HLY;P
MOX$L?"][-=VUU<2O-&(V$NW&`<]E%6/'8_XHG5AU_<'M71A@RY7!'L:Y[QW_
M`,B3JW_7`U;24=#BISE.M&4M[GBNAWMYX<O;/7+:/,#2M"P'_+0#&Y3[X.17
MT!IU]!J=A#>6L@DAF0,K#N*\U\%:'#X@^'M]8R\%KIVC<#E'`4AA^-1_#O79
M]%UB;PSJ7R9E(B!/"2=U'LPY'XUE3;C9=ST<9%5^9KXH_D>LN,J?I7C'P^0?
M\+%OL`<>>>G_`$T->S%AL)]J\;^'W_)1;[_MX_\`1E7._,CFPB_=5+]CV@=*
M6D[4M:G`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%
M`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`
M%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4
M444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!11
M10`AKC/B=_R)-U_O)_Z$*[/O7&?$[_D2;K_>3_T(5$_A9T87^-'U(OA8,^#E
M_P"N\O\`Z%7/?$G0)=/OXO$FG9C<.OG,@^ZX^Z_\@:Z'X5_\B<O_`%\2_P#H
M1KKKRSAOK.:VN(P\4J%&4]P:E1O!&\JSI8J4NES&\+^((_$7A]+Q!ME4;)HS
MU1QU']?QK@?A+_R,&J#_`*8C_P!#-4M.GN?A[XTDL;AF-A<$*6)X:,GY7^H)
MP:N?"4C_`(2#4\$%3%P1_OFL^:\DGN=,J/)2J2CL[-':?$B-I/!&H;<_*JL<
M>@8$UD_"21#X=NH\@NERV<>X!%=OJEE'J6F7-E*/W<\;(?Q%>,>%=6F\#^*I
M['4P5A<^5.?[I!^63_=QG\ZN>DTS'#_O<-*DM]SW2C.!5>*YBGB$L3JR,-P8
M'@CZU*S`+DD"MCS6FG8YSQU-%!X,U1Y!E3"4`]R<?SKF/@_$ZZ7J4A'R-.J@
M^X7G^8K*^)/BA-4GCT73SYT<;@S,G.^3H$7UP?Z5W_@S0VT+PS;6D@`N&'F3
MX_OMU'X<#\*Q^*I<]*2]CA.66\F9OQ!\&)XITE9+8*-2MP6@8\;QW4_7]*^>
MKB&6VF>">)XIHV*/&XPRD=1CUKZYQ[UY]\0/`$7B.`ZCIZ"+58T],"<?W6_V
MO0_A].NG.VY\]BL-SKFCN>=_">]-IXZAAW86ZB>)ORW?S6NG\5M_PE/Q'L]&
M0[H+<A)!V_O2?^.[1^->::'>/H?B2RO)XWC>SN%,L9X88.&4_J*]6^%MA)>W
M^I:_=#,LDA12?[Q.Y_Y@5GB%>21W90^2E.H^FAZ;L$=OM4`8&!7C'PVD%GXZ
MG@F&V1XY(@#_`'@VXC\A7MN.*\0\7V-UX2\;IK-HI\F:7[3&<X!8_?0^YY/T
M/UK"HK-,]'!2YE.GU:/;LCUIU8^B:[9Z_I\=W9R95OOH?O(W<$=C6OD5JG<X
M)1<79K4:Y&P_2O%/!O\`I'Q1EEC;*>;<OD#MG_Z]=WX[\6PZ%I3V\#AM1G0K
M$@/*`\;SZ#T]36!\)]#DB2YUF96`F_=0%NK*.2P]B?Y5E+WI)+H>CATZ6'G.
M771%;XP0MY^F2#E=LB#Z_*:]#\-3I=>&M-FC(VM;1].WRC(_I67X[T%]?\-R
M10KFZA/FPCN6`Y'XC(KCOAQXPBL`-"U%A"N\_9W;@`YY0^G/K[BCX9MA;VV%
M7+O$]=JO>7`M;*:X*EA$C/@=3@9J42*W0Y^E4M:/_$EO1ZP/_(UKT//BO>29
MB^$_&,7BM;DQ6DMO]G*@^8<YW9]/I6]JG_(+NO\`KDW\C7FGP;(VZKTY:+^3
M5Z5JG_(+N?\`KDW\JE.\;G15IJG7Y8GAO@WPI)XG:\$>H/9^1M^X"=V[=UY'
MI76'X37*\GQ!/_WP?_BJA^#W#ZMGC_4]O]^O5^#44X)HZ\7BZL:KBGH9?A_2
MVT31;;3WG:=H4VF5A@M5'QV/^*(U7_K@:Z'/8_C7/>.S_P`43JH_Z8&KDO=9
MP4I-UHM[W,/X2?\`(K7!_P"GM_Y+5#XG>&G*IXAL`4GAP)]G!P.C_5?Y5?\`
MA*N?"UQU_P"/M_Y+7=2PI/"\<J*Z.,,I&00>M*,;P2.BK6=+%.7F<WX,\2)X
MET!)78"[A_=W"XQSZ_0\?K7`_#W_`)*+??\`;?\`]&&H9$N/AUXY^3)TVXZ>
MAB)_FO\`GK4OPZ8/\0[UD(96$[`^JF3(/ZBLN;WDF=BHJ%.I./PM:'M/:EI.
MU+72>*%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!
M1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%
M%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`444
M4`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!112&
M@!M<WXYTJ[UKPO/9V**\[E2H9MHX8'K72XHP"*35U8JG-PDI+H<MX"TB\T3P
MTMG?QHDXF=MJMN&":ZFC''6EP*$K*P3FYR<GU..\>>%O^$ATG?;KF^MOFA[;
MO5?Q_P`*P?AKX<U;1M5O9=1M&@22%0I+`Y.[/:O3<>M&W%0Z:<N8WCBZD:+H
M]&'%<MXK\&6?B>(.2(+R,?NYU'Z-ZBNKI.U6TGHS"G4E3ES1>IX[!H?CWPH3
M'IK_`&BW!^58R'7_`+Y;I^%.N8?B/XA5K>9'M(6&&"E8E/XC+5Z_M%+MK/V7
MFSL6.>[BK]['!^$_AU;:'.M_?.MS?#E<+A(S[#UKNQQ2XHYQUJU%+1'+5JRJ
MRYI,6D(X/2G4AZ51F>0_%'P1<7-[!K.C6,L\TK;+B&$9).,A_P!,'\/Q]!\*
MZ0-$\/6=CM(D2/,F>NYN3^IK;V\]:`*'J3!<J:6S%K+UK1+/7=/>SO8]\;<@
M]T/9E/8UJ8H(HWT9<9.+NCQ^;P'XH\-WS77A^],J]@K;'*]@P/#8J1M0^)=P
M@M_LK1GH9!$BD_B37K>*-G^<5G[/LSL^NMZRBF_0\JT3X8WEY>_;O$MT9"S;
MGA5RQ<_[3'M[?K7I\,,=O"L42*D:`*JJ,``=JFP!151BD85L1.L_>88R*X/Q
M9\.;36Y)+RR=+6\<YD!7,<IQ_$/7W^O%=[S28XIM)DTJLZ3O%GC<.G?$3PZ/
M)M#+-$/N[765?P#<BII&^)6K(T#PF*-UVL"L:`@_G7KVT>@H"C'05G[+S9U?
M7GNX*_H<3\/_``G>^&K>[:^DA:2<J0L1)VX]2?K76WT;S6,\:#+,A`&>IQ5K
M%+WZU:C96.6=64Y\[W/%]*\)>.]"\W^S5@M_.QOQ)&V<9QU'H36G]E^*&/\`
MCZC_`#B_^)KU3%+@5'LUM=G0\;*6KBON.%\+P^-H]8)UZ=)+'RV``*?>R,?=
M`]ZWO%=A<:GX8U"SM4#3S0E4!;`S6UCFC%6HV5C"59N:FDD<C\/-%OM!T&:U
MU"-(YFN&D`5]W!`_P-=?2;13L4TK*R)J3=23D]V<QXS\,KXDT1X5P+N+,D#X
MZ-Z?0]/R/:N+^'GAC6=*\3?:KZR,,/D,N[>#\V17K1Y_*FA<-FI=-.5S:GBI
MPINGT9)1115G,%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444
M`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`
M4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1
M110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%
M%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444
M`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`
M4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1
M110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%
M%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444
M`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`
M4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1
M110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%
M%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444
M`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`
M4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1
%110!_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
